December 20, 2019: Novaliq GmbH

BAUSCH HEALTH LICENSES NOVALIQ’S NOV03 INVESTIGATIONAL TREATMENT FOR DRY EYE DISEASE ASSOCIATED WITH MEIBOMIAN GLAND DYSFUNCTION

Bausch Health Companies Inc. (“Bausch Health”) and Bausch + Lomb, its leading global eye health business, and Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, announced today that Bausch Health has acquired an exclusive license for the commercialization and development in the United States and Canada of the investigational treatment NOV03 (perfluorohexyloctane), a first-in-class investigational drug with a novel mechanism of action to treat Dry Eye Disease (DED) associated with Meibomian gland dysfunction (MGD).

Please read the whole article here
Novaliq GmbH

December 5, 2019: Apogenix AG

Apogenix to Present New Data on Asunercept at ESMO Immuno-Oncology Congress

Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that new data on its lead immuno-oncology candidate asunercept will be presented in a poster at the ESMO Immuno-Oncology Congress 2019, held from December 11-14, 2019, at the Palexpo in Geneva, Switzerland. The data are the result of a research collaboration with Benoit Van den Eynde and his team from the Ludwig Institute for Cancer Research in Brussels, Belgium.

Please read the whole article here
Apogenix AG

December 3, 2019: Joimax GmbH

joimax® Celebrates Resounding Success at the German Spine Society (DWG) Convention 2019

joimax®, the Germany-based market leader of technologies and training methods for full-endoscopic minimally-invasive spinal surgery, celebrated resounding success at this year’s German Spine Society (DWG), held November 28 to 30 in Munich, Germany. joimax® presented its newest product innovations and hosted several informative sessions to rave reviews, exceeding expectations.

Please read the whole article here
Joimax GmbH

December 2, 2019: CureVac AG

CureVac Granted Manufacturing Authorization for its Third GMP Production Suite

CureVac’s GMP I, II and III Combined Production Suite Scales Up Capacity to Meet All Preclinical, Clinical and Early Launch Needs for Proprietary and Partnered Programs

CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, announced today it received the manufacturing authorization for clinical trial materials produced under Good Manufacturing Practice (“GMP”) from the competent national authority, Regierungspräsidium Tübingen (as representative of the European Medicines Agency (EMA)), for the company’s scaled up GMP III production suite. This license marks CureVac’s third production suite to manufacture at the highest standard of pharmaceutical production in the world. CureVac’s GMP I, II and III production suites are located at CureVac’s corporate headquarters campus in Tübingen, Germany.

Please read the whole article here
CureVac AG

December 2, 2019: Cosmo Pharmaceuticals NV

Cosmo Pharmaceuticals announces worldwide exclusive Distribution Agreement for Eleview® with Medtronic

Cosmo Pharmaceuticals NV announced today that it has entered into a new worldwide supply and distribution agreement for Eleview® with Medtronic (with the exception of Japan and Canada, licensed respectively to EA Pharma and Pendopharm), having in the meantime terminated by mutual consent the co-marketing agreement with Fujifilm.

Please read the whole article here
Cosmo Pharmaceuticals NV

November 26, 2019: Cosmo Pharmaceuticals NV

Cosmo appoints New CSO as current CSO retires

Cosmo Pharmaceuticals N.V. today announced that Luigi Moro, its Chief Scientific Officer, is retiring and that Roberto Camerini MD will assume his responsibilities as of January 1, 2020.

Please read the whole article here
Cosmo Pharmaceuticals NV

November 14, 2019: AC Immune SA

AC Immune to Present at Jefferies 2019 London Healthcare Conference

AC Immune SA, a Swiss-based biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, today announced that it will present at Jefferies 2019 London Healthcare Conference in London, UK, taking place November 20 – 21, 2019.

Please read the whole article here
AC Immune SA

November 13, 2019: Cassiopea SpA

Cassiopea Announces First Patient to be Enrolled in Phase II Trial for the Treatment of Androgenetic Alopecia in Females with Clascoterone Solution

Cassiopea SpA, a specialty pharmaceutical company focused on developing and commercializing prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, announced today that it has received approval from the German Authority BfArM and the coordinating ethical committee and will now proceed to enrol the first patient in a Phase II trial investigating clascoterone solution for the treatment of androgenetic alopecia (AGA) in females.

Please read the whole article here
Cassiopea SpA

November 13, 2019: AC Immune SA

AC Immune Q3 2019 Financial Results and Business Update

CHF 32 Million in Milestone Revenues
Multiple Upcoming Catalysts
Execution Across Clinical and Preclinical Neurodegenerative Development Pipeline

AC Immune SA, a Swiss-based biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, today provided a business and clinical update and reported its consolidated financial results for the third quarter of 2019.

Please read the whole article here
AC Immune SA

November 8, 2019: Cassiopea SpA

Cassiopea Announces FDA Acceptance of its New Drug Application for Clascoterone Cream 1%, the First New Mechanism of Action for Acne in Nearly 40 Years

Cassiopea SpA, a specialty pharmaceutical company developing and commercializing prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, announced today the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for clascoterone cream 1%. Cassiopea is seeking marketing approval for clascoterone cream 1% for the treatment of acne. The FDA has set August 27, 2020 as the Prescription Drug User Fee Act (PDUFA) action date.

Please read the whole article here

Cassiopea SpA
Older Entries